Effect of Paclitaxel Combined with Cisplatin Intraperitoneal Circulation Thermoperfusion Chemotherapy on Tumor Markers and Prognosis in Patients with Ovarian Cancer
CUI Hong-jun, XIN Xiao-sen, ZHANG Shu-ze, et al
Department of Oncology and Hematology, Shandong Provincial Third Hospital,Jinan Shandong 250000
Abstract：【Objective】To investigate the effect of paclitaxel combined with cisplatin intraperitoneal thermal perfusion chemotherapy on tumor markers and prognosis in patients with ovarian cancer.【Methods】80 women diagnosed with ovarian cancer in our hospital were randomly divided into observation group and control group, with 40 cases in each group. The control group was treated with paclitaxel combined with cisplatin intravenous drip, and the observation group was treated with paclitaxel combined with cisplatin intraperitoneal circulation thermal perfusion. The curative effects of the two groups after 4 months of treatment were compared; The levels of serum carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), neuron specific enolase (NSE), carbohydrate antigen 125 (CA125) and kappa functional state score (KPS) were evaluated and compared between the two groups before and after treatment; The long-term survival and adverse reactions of the two groups were compared.【Results】the objective remission rate (ORR) in the observation group was 80.00% (32/40), which was significantly higher than 57.50% (23/40) in the control group (P<0.05). CEA, NSE and CA125 in the observation group were significantly lower than those before treatment and after treatment in the control group, and KPS scores were significantly higher than those before treatment and after treatment in the control group (P<0.05). The 1-year survival rate in the observation group was significantly higher than that in the control group (P<0.05). The total incidence of adverse reactions in the observation group was 80.00% (32/40), and there was no significant difference compared with 67.50% (27/40) in the control group (P>0.05).【Conclusion】Paclitaxel combined with cisplatin for intraperitoneal circulation thermal perfusion is more effective and safe, and has a positive impact on improving the prognosis of patients.
崔红军, 信晓森, 张淑泽, 洪玥琰. 紫杉醇联合顺铂腹腔循环热灌注化疗对卵巢癌患者肿瘤标志物及预后的影响[J]. 医学临床研究, 2021, 38(10): 1556-1559.
CUI Hong-jun, XIN Xiao-sen, ZHANG Shu-ze, et al. Effect of Paclitaxel Combined with Cisplatin Intraperitoneal Circulation Thermoperfusion Chemotherapy on Tumor Markers and Prognosis in Patients with Ovarian Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1556-1559.
2021, Vol. 38 
